Legal Opinion
Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA, Inc.
District Court, D. Delaware
Decided February 11, 2013No. Civil Action No. 10-805-CJBPublishedCited by 13 opinions
1Opinion of the Court
*608 MEMORANDUM OPINION
BURKE, United States Magistrate Judge.
INTRODUCTION
Plaintiff, Bristol-Myers Squibb Company (“BMS”), markets a medication under the trade name Baraclude® for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication, and either evidence of persistent elevations in serum aminotransferases or histologically active disease. (D.I. 135, ex 1 (hereinafter “Uncontested Facts”) at ¶¶ 21-23) The medication contains 0.5 mg and 1 mg of the compound entecavir in tablet form. (Id. at ¶ 22) The United States Food and Drug Administration’s…
2Cases cited64 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Stratoflex, Inc. v. Aeroquip CorporationCourt of Appeals for the Federal Circuit · 1983
- Therasense, Inc. v. Becton, Dickinson and Co.Court of Appeals for the Federal Circuit · 2011
59 more not listed; retrieve them via the Exa API.
3Cited by13 opinions
- Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2014
- Merck Sharp & Dohme Corp. v. Hospira Inc.District Court, D. Delaware · 2016
- AstraZeneca LP v. Breath Ltd.District Court, D. New Jersey · 2015
- Dey, L.P. v. Teva Parenteral Medicines, Inc.District Court, N.D. West Virginia · 2014
- Pfizer Inc. v. Mylan Pharmaceuticals Inc.District Court, D. Delaware · 2014
8 more not listed; retrieve them via the Exa API.